Dompé Farmaceutici is a privately held pharmaceutical company based in Milan.
[1] His son, Sergio Dompe is the current CEO.
[1] In 2012, Dompé acquired the eye health-focused Italian pharmaceutical company Anabasis Srl;[2] they went on to develop the Anabasis product cenegermin, an eye drop containing recombinant human nerve growth factor, as a treatment for neurotrophic keratitis.
[3] Cenegermin was approved by the FDA in August 2018 as the first available treatment for neurotrophic keratitis, and received orphan drug designation.
[4] In the same year, the company announced plans to list shares as part of its move to focus on biotechnology and the treatment of specific diseases.